SummitTX Capital L.P. Acquires 10,356 Shares of Establishment Labs Holdings Inc. $ESTA

SummitTX Capital L.P. raised its holdings in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 30.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 44,923 shares of the company’s stock after buying an additional 10,356 shares during the quarter. SummitTX Capital L.P. owned about 0.15% of Establishment Labs worth $2,551,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in ESTA. OMERS ADMINISTRATION Corp purchased a new stake in shares of Establishment Labs in the 1st quarter valued at about $238,000. Union Square Park Capital Management LLC boosted its position in shares of Establishment Labs by 16.7% during the 1st quarter. Union Square Park Capital Management LLC now owns 105,000 shares of the company’s stock valued at $5,962,000 after acquiring an additional 15,000 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Establishment Labs during the first quarter worth about $3,168,000. AlTi Global Inc. purchased a new position in shares of Establishment Labs during the first quarter worth about $842,000. Finally, KBC Group NV bought a new position in shares of Establishment Labs in the first quarter worth approximately $28,000. 72.91% of the stock is currently owned by institutional investors.

Establishment Labs Stock Performance

Shares of NASDAQ ESTA opened at $91.90 on Wednesday. The stock’s 50-day moving average is $83.63 and its 200 day moving average is $73.08. The stock has a market cap of $2.70 billion, a price-to-earnings ratio of -61.68 and a beta of 1.06. Establishment Labs Holdings Inc. has a 1-year low of $33.35 and a 1-year high of $96.99. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.10). Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The firm had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $57.40 million. During the same period in the prior year, the company earned ($0.70) EPS. The firm’s quarterly revenue was up 44.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Establishment Labs Holdings Inc. will post -1.07 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on ESTA. BTIG Research reaffirmed a “buy” rating on shares of Establishment Labs in a research note on Monday, July 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Citigroup increased their price target on shares of Establishment Labs from $76.00 to $92.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. TD Cowen restated a “buy” rating on shares of Establishment Labs in a research report on Monday, June 8th. Finally, Mizuho lifted their price objective on shares of Establishment Labs from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $90.43.

Insider Buying and Selling at Establishment Labs

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the company’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total value of $7,919,100.00. Following the completion of the sale, the director owned 927,504 shares of the company’s stock, valued at approximately $69,952,351.68. This represents a 10.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 180,000 shares of company stock valued at $13,225,275. Insiders own 9.99% of the company’s stock.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.